What is Zacks Research’s Estimate for Hologic Q2 Earnings?

Hologic, Inc. (NASDAQ:HOLX) – Analysts at Zacks Research raised their Q2 2026 EPS estimates for Hologic in a research report issued to clients and investors on Wednesday, September 17th. Zacks Research analyst Team now anticipates that the medical equipment provider will post earnings of $1.06 per share for the quarter, up from their previous forecast of $1.05. The consensus estimate for Hologic’s current full-year earnings is $4.28 per share. Zacks Research also issued estimates for Hologic’s FY2026 earnings at $4.39 EPS and FY2027 earnings at $4.78 EPS.

Several other brokerages have also weighed in on HOLX. Royal Bank Of Canada raised shares of Hologic from a “sector perform” rating to an “outperform” rating and increased their price objective for the company from $72.00 to $87.00 in a research report on Wednesday, August 6th. Morgan Stanley increased their price objective on shares of Hologic from $65.00 to $69.00 and gave the company an “equal weight” rating in a research report on Thursday, July 31st. Mizuho set a $75.00 price objective on Hologic in a research report on Thursday, July 31st. Wall Street Zen cut Hologic from a “buy” rating to a “hold” rating in a research report on Monday, September 15th. Finally, Evercore ISI increased their price objective on Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a research report on Tuesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat, Hologic currently has a consensus rating of “Moderate Buy” and an average target price of $79.38.

Hologic Price Performance

Shares of HOLX opened at $66.33 on Friday. The firm has a market capitalization of $14.75 billion, a PE ratio of 27.52, a PEG ratio of 2.47 and a beta of 0.57. The company’s 50-day moving average is $66.47 and its 200-day moving average is $62.75. Hologic has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS.

Institutional Trading of Hologic

Several large investors have recently bought and sold shares of HOLX. Nomura Holdings Inc. acquired a new stake in Hologic in the fourth quarter valued at about $551,000. Royal Bank of Canada raised its position in Hologic by 13.3% in the fourth quarter. Royal Bank of Canada now owns 442,769 shares of the medical equipment provider’s stock valued at $31,919,000 after purchasing an additional 51,898 shares during the last quarter. Tidal Investments LLC raised its position in Hologic by 38.3% in the fourth quarter. Tidal Investments LLC now owns 21,223 shares of the medical equipment provider’s stock valued at $1,530,000 after purchasing an additional 5,872 shares during the last quarter. Two Sigma Advisers LP raised its position in Hologic by 78.2% in the fourth quarter. Two Sigma Advisers LP now owns 31,000 shares of the medical equipment provider’s stock valued at $2,235,000 after purchasing an additional 13,600 shares during the last quarter. Finally, Squarepoint Ops LLC raised its position in Hologic by 657.8% in the fourth quarter. Squarepoint Ops LLC now owns 264,800 shares of the medical equipment provider’s stock valued at $19,089,000 after purchasing an additional 229,858 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.